Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy

The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high‐risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial.

[1]  J. Blay,et al.  Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. D. Dei Tos,et al.  Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Tao Jiang,et al.  Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST) , 2012, Investigative radiology.

[4]  Tim Meyer,et al.  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.

[5]  B. Morgan.  Opportunities and pitfalls of cancer imaging in clinical trials , 2011, Nature Reviews Clinical Oncology.

[6]  I. Ellis,et al.  Reproducibility in the diagnosis of needle core biopsies of non‐palpable breast lesions: an international study using virtual slides published on the world‐wide web , 2010, Histopathology.

[7]  S. Koscielny,et al.  Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography , 2010, Clinical Cancer Research.

[8]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[10]  V. Torri,et al.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. , 2009, Radiology.

[11]  F. Farrokhyar,et al.  A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.

[12]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[13]  J. Blay,et al.  Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial , 2007 .

[14]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Russo.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma , 2006 .

[17]  L. Schwartz,et al.  Imaging response assessment in oncology , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[18]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Buyse,et al.  Update in methodology and conduct of cancer clinical trials. , 2006, European journal of cancer.

[20]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Schuetze.  Imaging and response in soft tissue sarcomas. , 2005, Hematology/oncology clinics of North America.

[22]  A. Roddam.  Analysing Survival Data from Clinical Trials and Observational Studies , 2005 .

[23]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[25]  H. Brisse,et al.  Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment , 2004, Pediatric Radiology.

[26]  S Saini,et al.  Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. , 2003, Clinical radiology.

[27]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A R Padhani,et al.  Commentary. Are current tumour response criteria relevant for the 21st century? , 2000, The British journal of radiology.

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  A. Scarpa,et al.  Pathology and Genetics , 2010 .

[31]  R. Sylvester,et al.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .

[32]  D. Crowther.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997, The Lancet.

[33]  B. Escudier,et al.  Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[35]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[36]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  G. Alves,et al.  Pathology and Genetics , 1998 .

[39]  Y. Rolland,et al.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.

[40]  Linda Chami,et al.  Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. , 2011, Radiology.

[41]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[42]  L. Schwartz,et al.  How to assess anti-tumour efficacy by imaging techniques. , 2008, European journal of cancer.

[43]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[45]  M. Wendland,et al.  Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. , 1998, Radiology.

[46]  J. Hermans,et al.  Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma? , 1996, Skeletal Radiology.

[47]  H. Toutenburg.  Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .

[48]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .